Chemistry:Ianalumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | BAFF receptor |
| Clinical data | |
| Other names | VAY736 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ianalumab (INN;[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.[2][3][4]
This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.[5][6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.[7]
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117". WHO Drug Information 31 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf.
- ↑ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800037006.
- ↑ "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology 34 (1): 101485. February 2020. doi:10.1016/j.berh.2020.101485. PMID 32067925.
- ↑ "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology 32 (6): 609–616. November 2020. doi:10.1097/BOR.0000000000000754. PMID 33002950.
- ↑ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
- ↑ "Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab". 30 June 2023. https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-net-present-value/.
 |  |
